osa and tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, sample baseline characteristics of the SURMOUNT -OSA phase 3 trial 🚨‼️Study presented at @AmDiabetesAssn 🔴Tirzepatide

kola Kantonalne lige SBK/KSB:OFK Lugovi -...

Acarbose has been found to decrease some inflammatory parameters in diabetic patients

After a two-year-long shortage, the FDA announced that Eli Lillys GLP-1 drug Mounjaro, and obesity version Zepbound, are back in stock.

Oral GLP-1s and next generation medicines demonstrating higher clinical efficacy or tolerability will likely be positioned to capture premium segments, whereas the bulk of growth in price-sensitive markets like India, China, and Mexico will favour low-cost semaglutide

Current evidence suggests stopping these medications before conception, though individual circumstances vary significantly